- Current report filing (8-K)
November 10 2008 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported):
November 10, 2008
AVI BioPharma, Inc.
(Exact name of Company as specified in its
charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File No.)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification No.)
|
incorporation)
|
|
|
|
|
One S.W.
Columbia, Suite 1105
Portland,
OR 97258
(Address of principal executive offices)
(503)
227-0554
Registrants telephone number, including area
code
Not
Applicable
(Former name or former address, if changed
since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations
and Financial Condition.
On
November 10, 2008, AVI BioPharma, Inc. (the Company) issued a press
release announcing the Companys financial results for the third fiscal quarter
ended September 30, 2008. A copy of
the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 2.02, in Item 9.01 hereof and in Exhibit 99.1
shall not be deemed to be filed for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements
and Exhibits.
The
following exhibit is being furnished (not filed) herewith:
99.1
Press
release, dated November 10, 2008, entitled AVI BioPharma Announces Third
Quarter 2008 Financial Results
2
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Portland, State of Oregon, on November 10, 2008.
|
AVI
BioPharma, Inc.
|
|
|
|
By:
|
/s/
Leslie Hudson, Ph.D.
|
|
|
|
|
|
Leslie
Hudson, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Operating Officer)
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
release, dated November 10, 2008, entitled AVI BioPharma Announces
Third Quarter 2008 Financial Results
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024